{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-036697","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.775322+00:00","generated_at":"2026-06-08T21:49:05.740699+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sangamo reports updated Phase 1/2 Alta data for hemophilia A gene therapy; FVIII maintained through ~4 years","bullets":["Single infusion of giroctocogene fitelparvovec (3e13 vg/kg) maintains FVIII activity in mild-to-normal range through up to 208 weeks.","Mean annualized bleeding rate in high-dose cohort was 0 in year 1 and 1.2 overall; no participants resumed prophylaxis.","No confirmed FVIII inhibitor development, no thrombotic events, and liver safety resolved without sequelae.","Pfizer expects pivotal Phase 3 AFFINE trial readout in mid-2024.","Updated data to be presented at ASH Annual Meeting on December 11, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-036697","json":"https://secwatch.observer/filing/0001628280-23-036697.json","markdown":"https://secwatch.observer/filing/0001628280-23-036697.md","text":"https://secwatch.observer/filing/0001628280-23-036697.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828023036697/0001628280-23-036697-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828023036697/sgmo-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:49:05.740699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}